9 May 2016 - The SMC has today published advice accepting three new medicines for routine use in NHS Scotland.

Bevacizumab (Avastin) for advanced cervical cancer, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (Genvoya) for HIV, and adalimumab (Humira) for severe hidradenitis suppurativa (a chronic, inflammatory skin disease) were all accepted.

The Committee was unable to accept ivacaftor (Kalydeco) and lumacaftor-ivacaftor (Orkambi) for the treatment of cystic fibrosis. Ceftolozane-tazobactam (Zerbaxa), an antibiotic used to treat complicated bacterial infections of the abdomen, kidneys and urinary tract, was also not recommended.

For more details, go to: http://www.scottishmedicines.org.uk/About_SMC/Latest_news/News_Articles/May_2016_decisions_news_release